Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

BACKGROUND. Vascular endothelial growth factor and platelet-derived growth factor signaling in the tumor microenvironment appear to cooperate in promoting tumor angiogenesis. PATIENTS AND METHODS. We conducted a phase I trial combining bevacizumab (i.v. every 2 weeks) and imatinib (oral daily). Once...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Flaherty, Keith T., Hamilton, Betty K., Rosen, Mark A., Amaravadi, Ravi K., Schuchter, Lynn M., Gallagher, Maryann, Chen, Helen, Sehgal, Chandra, O’Dwyer, Peter J.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2015
Assuntos:
Melanoma and Cutaneous Malignancies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4524755/
https://ncbi.nlm.nih.gov/pubmed/26084808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0108
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados